🇺🇸 Ombitasvir-Paritaprevir-Ritonavir in United States
572 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 572
Most-reported reactions
- Renal Impairment — 88 reports (15.38%)
- Anaemia — 84 reports (14.69%)
- Hepatic Failure — 58 reports (10.14%)
- Fatigue — 56 reports (9.79%)
- Hyperbilirubinaemia — 56 reports (9.79%)
- Nausea — 53 reports (9.27%)
- Asthenia — 46 reports (8.04%)
- Pruritus — 46 reports (8.04%)
- Headache — 44 reports (7.69%)
- Jaundice — 41 reports (7.17%)
Ombitasvir-Paritaprevir-Ritonavir in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Virology/Hepatology approved in United States
Frequently asked questions
Is Ombitasvir-Paritaprevir-Ritonavir approved in United States?
Ombitasvir-Paritaprevir-Ritonavir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ombitasvir-Paritaprevir-Ritonavir in United States?
University of Modena and Reggio Emilia is the originator. The local marketing authorisation holder may differ — check the official source linked above.